Core Insights - Cognition Therapeutics, Inc. has developed a novel chemical process for manufacturing zervimesine (CT1812), enhancing its stability at room temperature and supporting future clinical studies and potential commercial manufacturing [1][2]. Group 1: Chemical Process and Patent Applications - The new manufacturing process utilizes innovative technologies such as high throughput screening and light-induced, continuous flow processing, which improves the efficiency and safety of zervimesine synthesis [2]. - Provisional patent applications have been filed for the new chemical process and a preferred polymorphic form of zervimesine [1]. Group 2: Zervimesine (CT1812) Overview - Zervimesine (CT1812) is an investigational oral medication aimed at treating central nervous system diseases, including Alzheimer's disease and dementia with Lewy bodies (DLB) [3]. - The drug targets the toxic effects of amyloid beta (Aβ) and ɑ-synuclein proteins, which are associated with neuron damage and cognitive decline in these diseases [3]. Group 3: Company Background - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [4]. - The company is currently investigating zervimesine in clinical programs for DLB and Alzheimer's disease, including the ongoing START study [4].
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)